title: Vaccines licensed and in clinical trials for the prevention of dengue.
abstract: Dengue has become a major global public health threat with almost half of the world's population living in at-risk areas. Vaccination would likely represent an effective strategy for the management of dengue disease in endemic regions, however to date there is only one licensed preventative vaccine for dengue infection. The development of a vaccine against dengue virus (DENV) has been hampered by an incomplete understanding of protective immune responses against DENV. The most clinically advanced dengue vaccine is the chimeric yellow fever-dengue vaccine (CYD) that employs the yellow fever virus 17D strain as the replication backbone (Chimerivax-DEN; CYD-TDV). This vaccine had an overall pooled protective efficacy of 65.6% but was substantially more effective against severe dengue and dengue hemorrhagic fever. Several other vaccine approaches have been developed including live attenuated chimeric dengue vaccines (DENVax and LAV Delta 30), DEN protein subunit V180 vaccine (DEN1-80E) and DENV DNA vaccines. These vaccines have been shown to be immunogenic in animals and also safe and immunogenic in humans. However, these vaccines are yet to progress to phase III trials to determine their protective efficacy against dengue. This review will summarize the details of vaccines that have progressed to clinical trials in humans.
authors.affiliation: a Department of Microbiology and Immunology , The Peter Doherty Institute for Infection and Immunity, University of Melbourne , Parkville , Victoria , Australia.
authors.forename: J
authors.initials: J
authors.lastname: Torresi
authors.affiliation: b The Walter and Eliza Hall Institute of Medical Research , Parkville , Victoria , Australia.
authors.forename: G
authors.initials: G
authors.lastname: Ebert
authors.affiliation: b The Walter and Eliza Hall Institute of Medical Research , Parkville , Victoria , Australia.|c Department of Medical Biology , The University of Melbourne , Parkville , Victoria , Australia.
authors.forename: M
authors.initials: M
authors.lastname: Pellegrini
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003715:Dengue / Q000517:prevention & control* / Q000821:virology; D053059:Dengue Vaccines / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology; D006801:Humans; D000071497:Immunogenicity, Vaccine; D008004:Licensure; D051379:Mice; D019595:Severe Dengue / Q000517:prevention & control*; D014613:Vaccines, Attenuated / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D022341:Yellow Fever Vaccine / Q000235:genetics / Q000276:immunology; D015005:Yellow fever virus / Q000235:genetics / Q000276:immunology
chemical_list: D053059:Dengue Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic; D022341:Yellow Fever Vaccine
keywords: dengue; dengue vaccines; immune response; neutralising antibody; preventative vaccination